Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

trastuzumab

- PMLiVE

EMA sets aside £32m for temporary staff to help with Brexit move

As agency warns current tender system needs to be updated

Eli Lilly HQ

Lilly gets early US approval for Ibrance rival abemaciclib

The breast cancer treatment, marketed as Verzenio, will also compete with Novartis' Kisqali

- PMLiVE

AbbVie deal with Amgen sets biosimilar Humira launch dates

Agreement will see Europe access the drug over four years earlier than patients in the US

- PMLiVE

EMA faces ‘permanent damage’ if forced to go to an unpopular city

Warns eight candidate cities wouldn't retain minimum staff numbers it needs

Roche Basel Switzerland

Roche’s Actemra/RoActemra receives new European approval

EU regulators also pass the Swiss pharma firm’s Gazyvaro

- PMLiVE

AbbVie and Roche plan Venclexta combo filings in leukaemia

MURANO trial shows the duo’s treatment extends PFS

- PMLiVE

Amgen’s Mvasi is first FDA-approved cancer biosimilar

Offers prospect of lower-cost alternative to Roche's Avastin

Biosimilars: what the future looks like

Biosimilars: what the future looks like

- PMLiVE

Roche faces prospect of second Rituxan biosimilar in US

FDA begins its review of Sandoz's version of the immunotherapy treatment

Eli Lilly HQ

Lilly’s abemaciclib data leaves potential uncertain

MONARCH 3 trial showed similar results to Pfizer’s Ibrance and Novartis’ Kisqali

- PMLiVE

Novartis scores but Roche misses in melanoma trials

Phase III trial combo success for Tafinlar/Mekinist “unprecedented”

Roche Basel Switzerland

UK is first to receive Roche’s rare lung cancer drug

Alecensa made available under MHRA's early access scheme

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links